Clayton S J, Scott F M, Walker J, Callaghan K, Haque K, Liloglou T, Xinarianos G, Shawcross S, Ceuppens P, Field J K, Fox J C
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.
Clin Chem. 2000 Dec;46(12):1929-38.
The use of sensitive molecular techniques to detect rare cells in a population is of increasing interest to the molecular pathologist, but detection limits often are poorly defined in any given molecular assay. We combined the approaches of real-time quantitative PCR with ARMS(TM) allele-specific amplification in a novel assay for detecting mutant K-ras sequences in clinical samples.
ARMS reactions were used to detect seven commonly occurring mutations in the K-ras oncogene. These mutations produce amino acid changes in codon 12 (Gly to Ala, Arg, Asp, Cys, Ser, or Val) and codon 13 (Gly to Asp). A control reaction was used to measure the total amount of amplifiable K-ras sequence in a sample so that the ratio of mutant to wild-type sequence could be measured. Quantitative data were confirmed for a selection of samples by an independent cloning and sequencing method. The assay was used to analyze 82 lung tumor DNA samples.
The assay detected K-ras mutations in 44% of adenocarcinomas, which is equivalent to frequencies reported in the literature using ultrasensitive techniques. Forty-six percent of squamous carcinomas were also positive. The ratio of mutant sequence in the tumor DNA samples was 0.04-100%.
The assay is homogeneous, with addition of tumor DNA sample being the only step before results are generated. The quantitative nature of the assay can potentially be used to define the analytical sensitivity necessary for any specified diagnostic application of K-ras (or other) point mutation detection.
分子病理学家越来越关注使用灵敏的分子技术来检测群体中的稀有细胞,但在任何给定的分子检测中,检测限往往定义不明确。我们将实时定量PCR方法与ARMS™等位基因特异性扩增相结合,开发了一种用于检测临床样本中突变K-ras序列的新型检测方法。
采用ARMS反应检测K-ras癌基因中7种常见的突变。这些突变导致密码子12(甘氨酸突变为丙氨酸、精氨酸、天冬氨酸、半胱氨酸、丝氨酸或缬氨酸)和密码子13(甘氨酸突变为天冬氨酸)发生氨基酸变化。使用对照反应来测量样本中可扩增K-ras序列的总量,从而能够测量突变型与野生型序列的比例。通过独立的克隆和测序方法对部分样本的定量数据进行了验证。该检测方法用于分析82份肺肿瘤DNA样本。
该检测方法在44%的腺癌中检测到K-ras突变,这与文献中使用超灵敏技术报道的频率相当。46%的鳞癌也呈阳性。肿瘤DNA样本中突变序列的比例为0.04%-100%。
该检测方法操作简单,加入肿瘤DNA样本是获得结果前的唯一步骤。该检测方法的定量特性有可能用于确定K-ras(或其他)点突变检测的任何特定诊断应用所需的分析灵敏度。